New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject

Michael S. Van Nieuwenhze; William W. Turner; Joseph L. Witztum; Karsten Hartvigsen

New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject

Michael S. Van Nieuwenhze (Opfinder), William W. Turner (Opfinder), Joseph L. Witztum (Opfinder), Karsten Hartvigsen (Opfinder)

Physiology of circulation, kidney and lung

Abstract

The present invention provides a peptide-phospholipid conjugate of Formula 1 wherein: X is selected from the group consisting of -CR1R2-, -NR3-, -O-, -S-, and -S+(R3)-; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.

Originalsprog	Engelsk
IPC	A61K-038/10
Patentnummer	WO2012108990-A2
Journaliseringsdato	16/08/2012
Land/Område	USA
Status	Udgivet - 2012

Citationsformater

@misc{a1d3cb929f774721a0682763ce2673f2,

title = "New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject",

abstract = "The present invention provides a peptide-phospholipid conjugate of Formula 1 wherein: X is selected from the group consisting of -CR1R2-, -NR3-, -O-, -S-, and -S+(R3)-; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.",

author = "{Van Nieuwenhze}, {Michael S.} and Turner, {William W.} and Witztum, {Joseph L.} and Karsten Hartvigsen",

year = "2012",

language = "English",

type = "Patent",

note = "WO2012108990-A2; A61K-038/10",

}

TY - PAT

T1 - New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject

AU - Van Nieuwenhze, Michael S.

AU - Turner, William W.

AU - Witztum, Joseph L.

AU - Hartvigsen, Karsten

PY - 2012

Y1 - 2012

N2 - The present invention provides a peptide-phospholipid conjugate of Formula 1 wherein: X is selected from the group consisting of -CR1R2-, -NR3-, -O-, -S-, and -S+(R3)-; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.

AB - The present invention provides a peptide-phospholipid conjugate of Formula 1 wherein: X is selected from the group consisting of -CR1R2-, -NR3-, -O-, -S-, and -S+(R3)-; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.

M3 - Patent

M1 - WO2012108990-A2

Y2 - 2012/08/16

ER -